ストックスクリーナーアプリを入手
53.78
0.94%
-0.51
プレマーケット:
54.14
0.36
+0.67%
Alkermes Plc (ALKS) 最新ニュース
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Alkermes plc Files 8-K Termination Report: Company Overview, NASDAQ Listing, and Key Details (July 2026) - Minichart
Alkermes plc outlines its role in neuroscience therapies as a global biopharmaceutical company - AD HOC NEWS
Insider Sell: David Gaffin Sells Shares of Alkermes PLC - GuruFocus
ALKS News | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
Alkermes stock hits 52-week high at 55.28 USD By Investing.com - Investing.com South Africa
Alkermes stock hits 52-week high at 55.28 USD - Investing.com
Alkermes (ALKS) EVP David Gaffin sells 2,034 shares under 10b5-1 plan - Stock Titan
Alkermes plc (ALKS) notice: David Gaffin lists proposed Common Stock sales in 2026 - Stock Titan
Price to earnings forward of Alkermes plc – NASDAQ:ALKS - TradingView
Granules India secures sole First-to-File status for generic drug - The Times of India
ALKSAlkermes plc Volatility & Greeks - Finviz
(ALKS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
The Bull Case For Alkermes (ALKS) Could Change Following Vibrance-12 Data And Russell 2000 Inclusion - simplywall.st
ALKS Maintains Rating by Mizuho -- Price Target Raised to $65 - GuruFocus
Mizuho raises Alkermes stock price target to $65 on narcolepsy drug potential - Investing.com
Alkermes (ALKS) R&D chief exercises 5,000 options and sells 9,000 shares - Stock Titan
Alkermes (ALKS) shows multiple 9,000-share insider sales, exercise and vesting - Stock Titan
Alkermes (ALKS) Is Up 9.3% After Strong Alixorexton Phase 2 Data And Russell 2000 AdditionWhat's Changed - Yahoo Finance
A Look at Alkermes PLC (ALKS) After 4.8% Decline -- GF Value $31 - GuruFocus
Alkermes plummets on mid-stage Alixorexton data for narcolepsy - MSN
ALKS Maintained by Wells Fargo -- Price Target Raised to $65.00 - GuruFocus
ALKS Downgraded by B of A Securities -- Rating Changed to Underp - GuruFocus
BofA downgrades Alkermes stock rating on valuation concerns By Investing.com - Investing.com Australia
BofA downgrades Alkermes stock rating on valuation concerns - Investing.com
REGBlackRock GroupSAR 6ALKERMES PLC - TradingView
Enterprise value to EBIT forward of Alkermes plc – NASDAQ:ALKS - TradingView
Press Release: Alkermes to Report First Quarter Financial Results on May 5, 2026 - Moomoo
Price to sales forward of Alkermes plc – NASDAQ:ALKS - TradingView
Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda - BioPharma Dive
What Does the Recent Insider Sale by Alkermes' VP of Finance Signify - Kavout | AI
Alkermes Public Limited Company Actuals & Estimates (NASDAQ:ALKS) - TradingView
ALKS Forecast — Price Target — Prediction for 2027 - TradingView
Alkermes stock hits 52-week high at 51.77 USD By Investing.com - Investing.com South Africa
Alkermes stock hits 52-week high at 51.77 USD - Investing.com
Liquidity Mapping Around (ALKS) Price Events - Stock Traders Daily
Alkermes Jumps 6.9% After Needham Maintains Buy - AlphaStreet
ALKS Maintained by Needham -- Price Target Raised to $61.00 - GuruFocus
Alkermes PLC (ALKS) Shares Surge 4.3% -- What GF Score of 70 Tel - GuruFocus
ALKS Maintained by TD Cowen -- Price Target Raised to $50 - GuruFocus
Alkermes plc (ALKS) Stock Analysis: Navigating Growth in Biopharmaceuticals with a 4.88% Upside - DirectorsTalk Interviews
Alkermes Plc (ALKS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alkermes presents detailed positive results from Vibrance-2 phase 2 study of Alixorexton in adults with narcolepsy type 2 at SLEEP 2026 - MSN
Alkermes announces orphan drug designations for Alixorexton in the US and Europe - MSN
Alkermes: "Buy" On Avadel Acquisition And Positive NT2 Data With Alixorexton (NASDAQ:ALKS) - Seeking Alpha
Did Positive Vibrance-2 Data for Alixorexton Just Shift Alkermes' (ALKS) Investment Narrative? - simplywall.st
Alkermes stock hits 52-week high at 45.76 USD By Investing.com - Investing.com India
1.63%
1.30%
大文字化:
|
ボリューム (24 時間):